Analyst firms · Morgan Stanley · ERAS
Morgan Stanley ERAS price target and rating history
Erasca Inc. (ERAS) · Health Care
Morgan Stanley rates Erasca Inc. (ERAS) Equal-Weight with a $2 price target, as of its latest action on Aug 18, 2025. It has published 3 rating actions on ERAS since August 2021, including 1 upgrade and 1 downgrade. Across 3 firms with a ERAS price target in the last 12 months, the median target is $16.
- Current rating
- Equal-Weight
- Price target
- $2
- Median target, all firms
- $16
- Actions on ERAS
- 3
Morgan Stanley price target on ERAS
Every Morgan Stanley rating on ERAS
- Aug 18, 2025
- Feb 3, 2023
- Aug 10, 2021
How other firms rate ERAS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BofA Securities | Neutral | $16 | Jun 4, 2026 |
| Mizuho | Outperform | $16 | Jan 27, 2026 |
| Piper Sandler | Overweight | $5 | Jan 7, 2026 |
Questions about Morgan Stanley and ERAS
- What is Morgan Stanley's price target for ERAS?
- Morgan Stanley's latest stated price target for Erasca Inc. (ERAS) is $2, from its action on Aug 18, 2025.
- What is Morgan Stanley's rating on ERAS?
- Morgan Stanley rates ERAS Equal-Weight, a neutral rating, as of Aug 18, 2025.
- When did Morgan Stanley last change its view on ERAS?
- On Aug 18, 2025, Morgan Stanley downgrades to Equal-Weight from Overweight, price target $2.
- How does Morgan Stanley's ERAS target compare with other analysts?
- Across 3 firms with a ERAS price target in the last 12 months, the median target is $16.
More ERAS rating histories
All Morgan Stanley ratingsERAS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.